Ars Pharmaceuticals Inc (SPRY)
NASDAQ (NMS) NASDAQ (NMS) Primary 
What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing'
ARS Pharmaceuticals, Inc. (SPRY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
ARS Pharmaceuticals, Inc. (SPRY) Q1 2025 Earnings Call Transcript
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Justin Chakma - CBO Richard Lowenthal - Co-Founder, President and CEO Eric Karas - CCO Kathleen Scott - CFO Conference Call Participants Ryan Deschner - Raymond James Josh Schimmer - Cantor Roanna Ruiz - Leerink Partners Lachlan Hanbury-Brown - William Blair Andreas Argyrides - Oppenheimer Louise Chen - Scotiabank Operator Good morning and welcome to ARS Pharmaceuticals' Conference Call. At this time, all participants are in listen-only mode.
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.11 per share a year ago.
ARS Pharmaceuticals Has A Blockbuster Candidate
ARS Pharmaceuticals has a recently launched needle-free epinephrine product for allergic reactions, neffy, and strong cash reserves. The company targets a ~$3B+ U.S. market, geographic expansion and intends to also address acute flares in chronic spontaneous urticaria. Financial projections include $500M peak U.S. sales, $500M outside the U.S., and $150M for chronic spontaneous urticaria, with profitability expected by 2027.
ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await
ARS Pharmaceuticals, Inc.'s stock surged 25% today after strong Q4 and full-year 2024 earnings, driven by the needle-free epinephrine treatment, neffy, which has promising market potential. Neffy's competitive edge lies in its innovative intranasal delivery, targeting a $3 billion initial addressable market in the U.S. with potential growth prospects. Despite neffy's potential, risks include competition, pricing pressures, and single-asset dependency, leading to a "Hold" recommendation due to commercial uncertainties.
ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call Transcript
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Justin Chakma - Chief Business Officer Richard Lowenthal - Co-Founder, President and CEO Eric Karas - Chief Commercial Office Kathleen Scott - CFO Conference Call Participants Ryan Deschner - Raymond James Alexa Deemer - Cantor Fitzgerald Louise Chen - Scotia Bank Roanna Ruiz - Leerink Partners Lachlan Hanbury-Brown - William Blair Julian Harrison - BTIG Operator Good day, and welcome to ARS Pharmaceuticals Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time all participants are in listen-only mode.
ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why.
Shares of ARS Pharmaceuticals bounded higher Thursday after the company reported an unexpected fourth-quarter metrics. The post ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move.
ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates
ARS Pharmaceuticals, Inc. (SPRY) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.07 per share a year ago.
ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions
ARS Pharmaceuticals launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions. Neffy's early sales also beat expectations, which I think showcases how much of a blockbuster it could become over time. Neffy targets several segments within severe allergic reactions and could also become an OTC medication soon. In total, this is a multibillion-dollar TAM.
ARS Pharmaceuticals, Inc. (SPRY) Q3 2024 Earnings Call Transcript
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Alex Straus - Investor Relations Richard Lowenthal - Co-Founder, President and CEO Eric Karas - Chief Commercial Office Kathleen Scott - CFO Justin Chakma - Chief Business Officer Conference Call Participants Josh Schimmer - Cantor Fitzgerald Ryan Deschner - Raymond James Roanna Ruiz - Leerink Partners Lachlan Hanbury-Brown - William Blair Operator Good day, and welcome to the ARS Pharmaceuticals Third Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode.
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.16 per share a year ago.
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024
On Saturday, Denmark-based ALK entered into a strategic license agreement with ARS Pharmaceuticals, Inc. SPRY.
